In a 34-year-old woman five months postpartum with Behçet’s disease presenting with fever, migratory arthritis, erythema nodosum, and oral/genital ulcers, what is the prognosis and do these symptoms usually resolve spontaneously?

Prognosis and Natural History of Behçet's Disease

Behçet's disease manifestations typically ameliorate over time in many patients, but the symptoms do NOT reliably resolve on their own without treatment—active management is essential to prevent irreversible organ damage and improve quality of life. 1

Understanding the Disease Course

Behçet's disease follows a relapsing and remitting pattern rather than a steadily progressive or self-limiting course 1. This is a critical distinction: while symptoms may wax and wane, the disease requires active suppression of inflammatory exacerbations to prevent permanent damage.

Prognosis Varies by Manifestation Type

The prognosis in your patient depends heavily on which organ systems are involved:

Favorable prognosis (mucocutaneous/joint involvement only):

• Skin, mucosa, and joint manifestations cause significant quality of life impairment but do not cause permanent organ damage 1
• In your patient with oral/genital ulcers, erythema nodosum, and migratory arthritis, these specific manifestations fall into this category
• Treatment can be tailored based on symptom impact versus medication risks 1

Poor prognosis indicators:

• Ocular, vascular, neurological, and gastrointestinal involvement can cause serious damage and even death if untreated 1
• Male sex, younger age of onset (before 25), and early disease onset predict more severe disease requiring aggressive treatment 1, 2

Do Symptoms Resolve Spontaneously?

No, active treatment is required. While the guidelines state that "disease manifestations usually abate over time" 1, this occurs in the context of appropriate treatment, not spontaneous resolution. The evidence is clear:

• The goal of treatment is to promptly suppress inflammatory exacerbations and recurrences to prevent irreversible organ damage 1
• Treatment may be tapered and even stopped during the disease course as manifestations abate, but this is after achieving control 1
• Without treatment, chronic oral and genital ulceration can cause scarring, leading to oropharyngeal narrowing and obliterative/deforming genital scarring 1

Specific Management for Your Patient

For this 34-year-old postpartum woman with mucocutaneous and joint involvement:

First-line treatment:

• Colchicine should be tried first for prevention of recurrent mucocutaneous lesions, especially when erythema nodosum or genital ulcers are dominant (Level of evidence: IB; Strength of recommendation: A) 1
• Topical steroids for symptomatic treatment of oral and genital ulcers 1

For refractory cases:

• Consider azathioprine, thalidomide, interferon-alpha, TNF-alpha inhibitors, or apremilast 1

Postpartum Considerations

Important caveat: The postpartum period presents unique challenges. While most pregnant patients experience disease remission 3, there are documented cases of:

• Worsening symptoms during pregnancy and postpartum 3
• Development of thrombotic complications in the postpartum period 4
• Reactivation of disease manifestations 5

Your patient's presentation at 5 months postpartum with active symptoms suggests she is experiencing a disease flare that requires treatment rather than expectant management.

Treatment Cannot Be Delayed

The evidence strongly supports early intervention rather than waiting for spontaneous resolution. The 2018 EULAR guidelines emphasize that treatment should be individualized based on symptom impact on quality of life versus medication risks 1, but this does not mean withholding treatment—it means choosing appropriate therapy intensity. For mucocutaneous disease causing significant symptoms (fever, multiple ulcers, erythema nodosum, arthritis), colchicine initiation is warranted immediately.